USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The validations confirm the completion of the applications and commence the scientific review process
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Acquisition of exclusive commercialization rights for European markets
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
iSolveSM information on demand is the result of our focus on customer relationship
Subscribe To Our Newsletter & Stay Updated